GeneDx Holdings Corp. (NASDAQ:WGS) is highlighted as one of the best digital health stocks to buy now. Guggenheim raised GeneDx’s price target to $170 after a strong Q3 performance with revenue hitting $116.7 million, up 52% year over year. The company specializes in genomic testing for pediatric and rare disorders, with a focus on whole-exome and whole-genome sequencing. Guggenheim also addressed the 2026 spending comments and reiterated a positive outlook for GeneDx.

Read more at Yahoo Finance: Guggenheim Reaffirmed Buy on GeneDx at October End, Lifted Price Target to $170 After Q3 Beat